It’s not always easy to choose the best medicine for a child. Some drugs are inappropriate for young patients, while others require special consideration or monitoring. For years, clinicians had only historical dogmas, word of mouth and their own experience to guide their choices. But a valuable new resource promises to change paediatric prescribing for the better. This episode is part of the Uppsala Reports Long Reads series – the most topical stories from UMC’s pharmacovigilance magazine, brought to you in audio format. Find the original article here. After the read, we speak to Rachel Meyers and David Hoff, who co-authored the KIDs List, to learn more about their work and the overall challenges of medicines safety in children. Tune in to find out: why adverse drug reactions tend to occur more often in the paediatric populationhow the KIDs List can improve prescribing for children how to collect even better safety information on paediatric drugs in the futureWant to know more? The KIDs List was first published in The Journal of Pediatric Pharmacology and Therapeutics, where you can find more information on how the list was compiled and how it is meant to be used. In an earlier commentary for the Journal of Pharmaceutical Sciences, Rachel Meyers reflects on the changes she’d like to see in how paediatric drugs are developed. In Europe, the conect4children (c4c) project aims to speed up and facilitate high-quality clinical trials in children while ensuring that the voices of young patients and their families are heard. Finally, don’t forget to ­subscribe to the monthly Uppsala Reports newsletter for free regular updates from the world of pharmacovigilance. Join the conversation on social media Follow us on Twitter, Facebook, or LinkedIn and share your thoughts about the show with the hashtag #DrugSafetyMatters. Got a story to share? We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch! About UMC Read more about Uppsala Monitoring Centre and how we work to make medicines safer for patients.